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Plerixafor is an effective haematopoietic stem cell mobilising agent in candidates for autologous transplantation,
including patients with myeloma and lymphoma. Here we compare 98 plerixafor recipients in the PHANTAS-
TIC trial with 151 historic controls mobilised by conventional chemotherapy (each with granulocyte colony-
stimulating factor, G-CSF). Seventy (71.4%) plerixafor-mobilised patients achieved the composite primary end-
point of 4 3 106 CD341 cells kg21 in 2 aphereses and no clinically significant neutropenia, compared to 48
(31.8%) historic controls (P< 0.001), and this significant advantage was maintained in scenario analyses testing
components of this composite endpoint. A patient-level cost analysis was undertaken for 249 patients, which
included the cost of remobilising patients where initial mobilisation had failed. Combined mean treatment cost
for plerixafor mobilised patients was £12,679 compared with £11,694 for historical controls. However, plerixafor
produces an average saving of £3,828 per lymphoma patient but average cost increase by £5,245 per myeloma
patient. The present data demonstrate cost-effectiveness for plerixafor as a first line mobilisation agent, certainly
for lymphoma patients, where substantial resource savings and achievement of the primary endpoint are likely.
J. Clin. Apheresis 31:434–442, 2016. VC 2015 Wiley Periodicals, Inc.
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INTRODUCTION
The outlook for many haematological malignancies
has steadily improved over the last couple of decades,
due to both newer treatment agents and also better man-
agement of their side effects [1–3]. The mainstay of
treatment is standard chemotherapy, which is typically
given as several cycles lasting 3–6 months. Unfortu-
nately, such first-line chemotherapy is not always cura-
tive as a proportion of patients achieve a remission, but
subsequently relapse [4]. Many will respond to further
chemotherapy often at much higher doses to give the
best chance of cure. Life-threatening marrow aplasia
associated with this high-dose chemotherapy is mitigated
by infusing haematopoietic stem cells shortly after com-
pletion of the high-dose chemotherapy. In the case of
multiple myeloma and lymphomas [both Hodgkin’s dis-
ease (HD) and non-Hodgkin lymphoma (NHL)], it is
standard practice to use the patient’s own stem cells
[5–7]. Strictly speaking, the entire procedure is “high-
dose chemotherapy with autologous stem cell rescue,”
but this is usually colloquially termed “autografting” or
autologous stem cell transplantation (ASCT).
It is of course essential to collect and cryopreserve suf-
ficient stem cells, prior to commencing the high-dose
chemotherapy component of the autograft. Detection of
the antigen CD34 is widely used as a marker of early hae-
matopoietic cells, and the CD341 population contains the
stem cells responsible for long-term marrow recovery
post autografting. It is generally accepted that 2 3 106
CD341 cells per kg of recipient weight is the minimum
dose for satisfactory engraftment, but doses up to 4 3 106
CD341 cells kg21 may lead to more rapid engraftment;
doses higher than this may not achieve any additional
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clinical advantage [8,9]. Formerly, these CD341 cells
were collected by aspirating several hundred mls of mar-
row under general anaesthesia, but nowadays most units
prefer to mobilise these CD341 cells into the blood-
stream, as haematopoietic stem cells from this source
engraft more quickly and also due to practical considera-
tions and patient preference. These cells are collected by
harvesting the mononuclear fraction of the blood by stand-
ard leukapheresis [10,11].
Several strategies have been used to mobilise CD341
cells into the bloodstream. Granulocyte colony stimulat-
ing factor (G-CSF) alone may be used, especially for
patients with myeloma. However, CD341 yields are
improved by giving “mobilising” chemotherapy together
with G-CSF, and this strategy is common in Europe [12].
A single dose of cyclophosphamide is widely used
as mobilising chemotherapy, especially in myeloma; for
lymphoma patients who are responding to salvage (sec-
ond or subsequent line) chemotherapy, a further course
of salvage chemotherapy is often used instead [13,14].
The mobilising agent plerixafor competes for C-X-C
chemokine receptor type 4 (CXCR4), which is expressed
on CD341 cells. Its ligand, stromal cell derived factor 1
(SDF-1), is expressed on marrow stroma, and this interac-
tion is important for CD341 cell adherence in the marrow.
Several studies have shown that plerixafor with G-CSF can
mobilise CD341 cells in sufficient numbers to support an
autograft [15–18] and these include randomised studies
showing that plerixafor with G-CSF is superior to G-CSF
alone [8,12,19,20]. However, plerixafor has not been com-
pared to conventional chemotherapy (each with G-CSF).
Our study of Plerixafor Harvesting And No chemoTherapy
for Autologous Stem cell Transplantation In Cancer (acro-
nym5PHANTASTIC) examined CD341 cell mobilisa-
tion in 98 patients with myeloma, HD or NHL, and
compared the findings with 151 immediately preceding
consecutive historic controls mobilised with conventional
chemotherapy. The findings on efficacy and toxicity have
recently been reported in Clark et al. [21]. Here we sum-
marise these findings and extend them to include a health
economic comparison between plerixafor and conventional
chemotherapy using individual patient level data.
METHODS
Clinical Details of PHANTASTIC and Historic
Control Group
The full eligibility criteria for entry into PHANTAS-
TIC and the historic control group have recently
reported [21]. Briefly, these were; patients with under-
lying myeloma or lymphoma (either HD or NHL),
aged 18, in whom ASCT was intended as their next
course of treatment. Patients were ineligible if they had
undergone any prior attempt at harvesting for the cur-
rent transplant. Entry took place between April 2010
and June 2012. Trial entrants received non-pegylated
G-CSF from Day 1 for 5–8 days as needed, and plerix-
afor daily from Day 4 for 1–4 days as needed; stem
cell collection was performed daily beginning on Day
5, until either the target stem cell number (4 3 106
CD341 cells kg21) was collected or four leukapheresis
procedures had been performed. All drug doses were
standardised, as previously reported [21].
The historic control group comprised all 151 immedi-
ately preceding consecutive patients in whom stem cell
mobilisation was undertaken, and who would have fitted
the PHANTASTIC eligibility criteria, back to November
2006. They received non-pegylated G-CSF at the same
dose, together with mobilising chemotherapy. The latter
was either a single dose of intravenous cyclophosphamide
together with MESNA (used to protect the lining of the
bladder) or a further course of salvage chemotherapy to
which the patient was already known to be responding, in
line with standard practice. Unless clinically contraindi-
cated, historical control patients who mobilised <4 3 106
CD341 cells kg21 in their first harvest round underwent a
second round of harvesting, and those who thereafter still
did not yield the minimum safe level of 2 3 106 CD341
cells kg21 underwent a third round of harvesting. However,
plerixafor became available as a second-line harvesting
strategy in 2008 (during the accrual of the 151 historic con-
trols). Therefore, two comparator control groups were
defined: the perprotocol group of 140 patients (control
Group 1) which omits the 11 patients (6 myeloma, 5 NHL)
who received plerixafor as second-line mobilisation, and
control Group 2 comprising the entire historical control
cohort of 151 patients. Patients in the trial group were retro-
spectively matched with patients in the control group, this
was to reduce confounding and strengthen the evidence
produced from the study in the absence of a randomised
controlled trial.
The primary study endpoint was a composite of both an
optimal stem cell harvest (4 3 106 CD341 cells kg21 in
no >2 aphereses) and a neutrophil count that never fell
below 1.0 3 109/Litre in the 3 weeks following initiation
of mobilisation. In addition to the previously reported clini-
cal analysis centred on the primary composite outcome,
three scenario analyses, stratified for each disease sub-
group (myeloma, HD and NHL), were conducted to
explore whether the patients failing the composite primary
endpoint might have passed its individual elements.
Economic Analysis
The economic analysis compared the outcomes and
costs of patients mobilised by plerixafor and G-CSF in
the PHANTASTIC trial with the historical control arm
who received conventional chemotherapy and G-CSF.
Treatment costs and outcomes from any secondary or
tertiary mobilisation attempts are included in the analy-
ses, as these are part of normal clinical practice for
ASCT. All clinical and economic data were reviewed
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and quality checked by at least two research personnel
before inclusion into the database.
First, a detailed patient-level cost analysis was under-
taken for each patient in both groups. The analysis eval-
uated resource use from the first dose of G-CSF
(PHANTASTIC trial patients) or the beginning of the
mobilising chemotherapy schedule (historic control
patients), up to and including the end of stem cell collec-
tion. It was not possible to assess the extent to which pler-
ixafor might have altered clinical outcome or not (e.g.,
overall or relapse free survival), since patients were not
routinely followed beyond 12 months after their transplant.
The analysis is therefore a cost-effectiveness study (cost
per patient achieving a stem cell yield sufficient to support
a subsequent transplant), and contributes to the increasing
evidence about the cost-effectiveness of plerixafor in
myeloma and lymphoma patients [22–28].
The cost analysis identified the resources used for
each of the 249 patients, comprising stem cell aphere-
sis, processing and freezing, pharmaceutical costs of
plerixafor, chemotherapy, G-CSF, drugs used to miti-
gate adverse events, associated plerixafor and chemo-
therapy administration and their supportive medication
costs, blood tests to assess CD341 numbers, and bone
marrow harvesting. The unit costs were collected from
a variety of sources, which included the hospital finance
department, the British National Formulary and UK
National Health Service reference costs. To complete
the cost analysis the following assumptions were made:
 The standard dose of plerixafor was 240 mg kg21
recipient weights and each vial contained 24 g of
plerixafor. Because of drug accountability issues
within clinical trials, plerixafor vial sharing was not
permitted within the PHANTASTIC trial patients,
and therefore the minimum vial usage per apheresis
day was one, and patients over 100 kg required two
vials. In normal NHS practice, it may be possible to
use residual vial contents for other patients, reducing
plerixafor costs. Even if vial sharing is a pragmatic
cost-saving solution that may be justified by users, it
is legitimately important to note that the official
description of the product advises against the practice.
 In the absence of specific data on individual patient G-
CSF dosing, historic control patients were assumed to
receive 4 days of G-CSF before stem cell harvesting
(plus that given during each additional day of stem
cell harvest). Patients who required a subsequent
round of stem cell mobilisation were assigned an addi-
tional 4 days of G-CSF (plus additional days if addi-
tional collections). It is possible that these patients
received higher than standard (5 mg kg21) doses of
G-CSF and therefore the costs for the historic control
group may be underestimated. No G-CSF was
assigned if undergoing bone marrow harvesting, but
instead the costs of operating theatre access and gen-
eral anaesthesia, etc., were included.
 For relapsed patients, our policy for the duration of
both the historic control group and the PHANTASTIC
trial has been to wait for objective evidence that the
patient is responding to salvage chemotherapy, before
commencing stem cell mobilisation. This was to avoid
unnecessarily harvesting patients with refractory dis-
ease, who would be unsuitable for subsequent ASCT.
The chemotherapy schedule used for stem cell mobili-
sation in historic control patients was therefore addi-
tional to that required for salvage. However, it was not
always possible to verify the point at which a decision
was made to proceed to stem cell mobilisation. It was
therefore assumed that the patient’s final chemother-
apy cycle was solely to mobilise stem cells; its costs
(but not those of earlier salvage chemotherapy cycles)
were included in the analysis.
 Every historic control patient receiving mobilising chem-
otherapy required a hospital stay. It was assumed that the
duration of the hospital stay was dependent upon the
chemotherapy type received, as the length of individual
patient hospital stays was not always for clinical reasons
(e.g., patients living distant from our hospital) yet such
reasons were not always recorded. Chemotherapy admin-
istration costs were incorporated into the overall costs,
although the different chemotherapy schedules required
varying administration times. The most appropriate cost
available from the healthcare resource groups (HRG)
was the day case administration cost for “Malignant dis-
orders of Lymphatic/Haematological system (without
complications or comorbidities),” which was £362. This
cost was considered appropriate for cyclophosphamide
mobilised patients as these only require 1 day.
 Several chemotherapy schedules required some addi-
tional costs for safe delivery, such as MESNA for
cyclophosphamide or ifosfamide, calcium supplemen-
tation during apheresis, and intravenous giving sets,
for example. As information on these was not always
available, associated costs were allocated to each
patient depending on treatment.
RESULTS
Patient demographics (sex, age, and BMI) were sim-
ilar between the PHANTASTIC trial patients and the
historic controls, which can be seen in Table I. Clinical
outcomes based on a series of scenario analyses are
reported below, along with comparative resource use
and a cost-effectiveness analysis.
Clinical Outcomes
Full details of the proportion of patients achieving
the primary composite endpoint have been previously
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reported [21], and are summarised in Table II, addi-
tionally giving the proportions in each of the historic
control groups 1 and 2. The proportion achieving the
primary composite endpoint was significantly higher in
the plerixafor mobilised PHANTASTIC trial patients
than in either historic control group (P< 0.0001; z test
for proportions; two samples), with more than twice as
many PHANTASTIC NHL patients achieving the pri-
mary endpoint than in the historical control groups, for
example. Moreover, all the PHANTASTIC trial patients
required only one stem cell harvest round and required, a
lower mean number of apheresis days. Overall, a higher
proportion of myeloma patients achieved the primary
endpoint than NHL patients (P< 0.01). One possible
reason for this is that mobilisation in myeloma is usually
attempted in first response/remission, unlike lymphomas
where this is usually done in second or subsequent
response/remission; the latter are therefore more heavily
pre-treated [21,24].
Scenario Analyses of the Primary Composite
Endpoint Components
Three scenario analyses were undertaken to explore
the proportion of patients passing the individual ele-
ments of the composite primary outcome [29,30].
These are given in Table II.
The first scenario analysis was designed to test the
number of patients achieving a minimum harvest without
clinically significant neutropenia. It altered the endpoint
to the harvesting of adequate cells to support an ASCT
(23 106 CD341 cells kg21 rather than 4 3 106) and the
number of apheresis collection days to 4 days rather
than 2, but still with the same cut-off for neutropenia.
As shown in Table III, not surprisingly, the proportion of
patients passing this increased (94.9% in PHANTASTIC
trial vs. 75.7% in historic control Group 1 and 76.2% in
historic control group 2). However, the qualitative
relationship between the groups remains similar and a
similar effect is seen in each of the disease subgroups.
TABLE I. Comparison of Baseline Characteristics Between the
Plerixafor Mobilised PHANTASTIC Trial Group and Each of
the Historical Control Groups (Group 1 Excludes the 11
Patients Who Received Second Line Plerixafor; Group 2
Includes all 151 Cases)
PHANTASTIC
trial
Historic
control
group 1
Historic
control
group 2
Number of cases 98 140 151
Sex (M/F) 60/38 87/53 92/59
Median age (range) 56 (20–68) 54 (19–70) 55 (19–70)
BMI (average) 26.5 27.4 27.2
BMI5 body mass index, defined as: [weight in kilograms]/[height in
metres]2.
TABLE II. Proportion of the Plerixafor Mobilized PHANTASTIC Trial Group and Each of the Historical Control Groups who
Achieved: The Primary Composite Endpoint
(a) Primary composite
endpoint
(b) Scenario
analysis 1
(c) Scenario
analysis 2
(d) Scenario
analysis 3
PHANTASTIC trial group
HD (%) 11/14 (79) 13/14 (93) 11/14 (79) 13/14 (93)
NHL (%) 21/39 (54) 36/39 (92) 22/39 (56) 37/39 (95)
Lymphoma (HD1NHL) (%) 32/53 (60) 49/53 (92) 33/53 (62) 50/53 (94)
Myeloma (%) 38/45 (84) 44/45 (98) 38/45 (84) 44/45 (98)
All Patients (%) 70/98 (71) 93/98 (95) 71/98 (72) 94/98 (96)
Historic control group 1
HD (%) 6/21 (29)*** 16/21 (76) 15/21 (71) 17/21 (81)
NHL (%) 10/48 (21)*** 29/48 (60) 24/48 (50) 34/48 (71)***
Lymphoma (HD1NHL) (%) 16/69 (23)*** 45/69 (65)*** 39/69 (56) 51/69 (74)***
Myeloma (%) 32/71 (45)*** 61/71 (86)** 39/71 (55)** 65/71 (92)
All Patients (%) 48/140 (34)*** 106/140 (76)*** 78/140 (56)*** 116/140 (83)***
Historic control group 2
HD (%) 6/21 (29)*** 16/21 (76) 15/21 (71) 17/21 (81)
NHL (%) 10/53 (19)*** 32/53 (60) 24/53 (45) 37/53 (70)***
Lymphoma (HD1NHL) (%) 16/74 (22)*** 48/74 (65)*** 39/74 (53) 54/74 (73)***
Myeloma (%) 32/77 (42)*** 67/77 (87)** 39/77 (51)*** 71/77 (92)
All patients (%) 48/151 (32)*** 115/151 (76)*** 78/151 (52)*** 125/151 (83)***
P< 0.015 *** P< 0.055 ** P< 0.105 * (z test for two population proportions).
Scenario Analysis 1: a cell yield 2 3 106 CD341 cells kg21 in 4 or fewer days (but the same neutropenia criterion as the primary
composite endpoint). This tests the number of patients achieving a minimum harvest without clinically significant neutropenia.
Scenario Analysis 2: a cell yield of 43 106 CD341 cells kg21 in 2 days (i.e., the same as the primary composite endpoint) but with no stipulation
about neutropenia. This tests the proportion who would have passed the primary composite endpoint were it not for the emergence of neutropenia.
Scenario Analysis 3: a yield of 2 3 106 CD341 cells kg21 irrespective of the number of aphereses or evidence of neutropenia. This tests
solely the number of patients achieving a minimum harvest to support a subsequent ASCT.
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The second scenario analysis in Table II tested the pro-
portion of patients who would have passed the primary
composite endpoint were it is not for the emergence of
neutropenia. It utilised the same stem cell mobilisation
and number of apheresis days thresholds as the primary
composite endpoint, but with no stipulation concerning
neutropenia. In the PHANTASTIC trial patients, there
was only one patient who failed to achieve the primary
composite endpoint solely due to neutropenia (and this
was likely to be disease-related rather than plerixafor-
induced), whereas in the historic controls (control 1 and
control 2) 30 more patients (mostly lymphoma) would
have achieved the composite primary outcome if neutro-
penia had not been a component.
The third scenario analysis was designed to test
solely the number of patients achieving a minimum
harvest (2 3 106 CD341 cells kg21) to support a sub-
sequent ASCT; it removed any criteria for apheresis
days or neutropenia. The proportion of patients achiev-
ing this less rigorous outcome is now higher, but there
was still a significant advantage (P< 0.01) for PHAN-
TASTIC trial patients over both historic control groups
1 and 2 (95.9% vs. 82.9% and 82.8%) and this differ-
ence was again seen in each disease subgroup.
Comparative Resource Use
Table III compares the mean costs for the PHANTAS-
TIC trial patients with the mean costs in the historic con-
trol groups 1 and 2. The mean costs for all PHANTASTIC
patients were £12,679, compared to £11,182 and £11,694
(P< 0.01) in historic control groups 1 and 2, respectively.
For PHANTASTIC trial patients, since no overnight inpa-
tient stay or supportive medication for chemotherapy is
required, their dominant cost was that of plerixafor itself.
Their overall costs are therefore highly sensitive to the
actual cost of plerixafor; the most costly subgroup was in
NHL (mean cost £15,425 per patient of which the mean
plerixafor component was £12,144). Myeloma patients in
the PHANTASTIC trial group had the least expensive
average patient cost of £10,705 of all the mobilising sched-
ules, which requires the shortest hospital stay and support-
ive medication regime. In the historic control groups 1 and
control 2, HD patients were the most costly subgroup to
treat at £19,241 (primarily due to the inpatient hospital
stay resulting from their mobilising chemotherapy), while
myeloma patients were the least costly. Moreover,
between the PHANTASTIC trial and both historic control
groups, the resource use costs were found to be signifi-
cantly higher for lymphoma patients over myeloma
patients (P< 0.01).
Although not currently recommended according to the
official product description of plerixafor, vial sharing is
considered feasible by some clinicians provided that the
vial is stored in sterile conditions of aseptic pharmacies. If
we assumed that vial sharing would be possible withoutT
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waste, in HD and NHL patients, mean resource use would
reduce to £9317 and £12,779, while in myeloma patients,
mean resource use would reduce to £9209. Therefore, the
average cost of PHANTASTIC trial patients would
decrease to £10,783 which represents a significant cost-
saving (P< 0.01) when compared to both historical con-
trols. Less than perfect vial sharing may still result in
absolute cost savings, but not of the same magnitude.
Incremental Cost-effectiveness Ratios
The incremental cost-effectiveness ratio (ICER)
involves a comparison of separate treatments which is
defined as the ratio between the difference in costs and
the difference in effects of two interventions or strategies.
The ratio is used to highlight the cost-effectiveness of a
health care intervention and is used as a decision rule in
resource allocation. Table III compares both the incre-
mental costs and incremental effects between the PHAN-
TASTIC trial and the historic control groups (see Table
IV for description of methodology) [31].
The incremental effects refer to the average proportion
of patients who achieve the primary composite endpoint.
Lymphoma patients in the PHANTASTIC trial were more
successful than historic controls in achieving the primary
endpoint and this was achieved at a lower cost. This effect
was seen for both the HD and NHL patients. In contrast,
myeloma patients in the PHANTASTIC trial had an incre-
mental cost of £15,450 and £12,608 vs. historic control
groups 1 and 2, respectively per additional successful
stem cell collection (see Table III) [23]. Similarly, when
comparing lymphoma patients in the PHANTASTIC trial
with historic control Group 1 and 2, the trial group domi-
nated as they were both cheaper and more patients
achieved the primary endpoint. Total patients in the
PHANTASTIC trial had an incremental cost of £4,030
and £2,487 vs. historical controls 1 and 2, respectively per
additional successful stem cell collection. As discussed, if
vial sharing was permitted and enabled the most efficient
usage of the drug, the treated group as a whole would
likely demonstrate cost-savings and therefore dominate
the control groups.
DISCUSSION
The PHANTASTIC study and its comparison to historic
controls was undertaken to compare first line plerixafor
with conventional chemotherapy for stem cell mobilisa-
tion. The clinical data [21] reinforced earlier reports that
plerixafor is highly effective and with low toxicity. How-
ever, the treatment cost is sometimes higher than in the
alternative treatment strategies due to the price of plerixa-
for. The treatment decision in some European countries is
therefore not only based on the clinical results, but on eco-
nomic considerations as well. The present economic analy-
sis was therefore undertaken to explore patient level
resource use in the same PHANTASTIC trial and historic
control patients.
We report that the mean treatment costs in the PHAN-
TASTIC trial group were £12,679 compared with
£11,182 in historic control Group 1 (which excludes
recipients of plerixafor). However, plerixafor is licensed
for second line and also for “pre-emptive” use, in
patients who are not mobilising well to their primary
mobilisation strategy. None of the present controls
received pre-emptive plerixafor, but 11 cases received it
second line. When these cases are also included in the
historic control cohort (Group 2), which is more reflec-
tive of present day practice, their treatment cost becomes
£11,694, i.e., marginally lower than that for first line
plerixafor. Compared with conventional chemotherapy
mobilisation, first line plerixafor enabled a higher pro-
portion of patients to achieve the primary composite out-
come in all three disease subgroups, with cost savings in
lymphoma patients but an incremental cost in myeloma
patients of £6,083 (and £5,245 when the 11 second line
plerixafor cases are included in the historic control
group).
In terms of cost-effectiveness, lymphoma patients who
received plerixafor were dominant as more patients
achieved the primary composite endpoint (or any of the
scenario analyses) and at a lower cost. The key cost driver
between lymphoma and myeloma patients was duration
of hospital stay when stem cell mobilisation was under-
taken. The assumption of 4 days of G-CSF before stem
cell harvesting in the control group does not appear to be
a big cost driver overall. These findings support the
TABLE IV. Description of the Methodology for Conducting Cost-effectiveness Analysis
Costing items in PHANTASTIC patient group (PG) e.g., Plerixafor, GCSF, apheresis, supportive care
Costing items in historical control groups 1 & 2 (CG) e.g., GCSF, chemotherapy, hospital stay for chemotherapy,
apheresis, supportive care
Average cost for each group Total costs
Number of patients
Successful Collection rate for each group Number of successful collections
Number of patients
ICER Average cost PGð Þ2Average cost CGð Þ
Collection rate PGð Þ2Collection rate CGð Þ
Discount rate Not applicable (less than 1-year time horizon)
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adoption of plerixafor as a first line stem cell mobilisation
strategy, certainly for lymphoma patients where substan-
tial savings are likely. It may be possible that the savings
made for lymphoma can patients can offset the increased
expenditure for myeloma patients; this is however sensi-
tive to the relative proportions of lymphoma to myeloma
patients in individual transplant teams, with the proportion
of myeloma patients in the cohort higher than we would
expect on average (NICE, 2010). An additional reason for
favouring first line plerixafor, which is difficult to for-
mally evaluate clinically or economically, is that the
decreased number and better “predictability” of the aphe-
resis days needed for an individual patient can help with
day to day practical planning for the clinical, apheresis,
and cryopreservation teams and may increase throughput
[32–34].
The present study uses historic controls. During the
overall period of the present study (Nov 2006 to June
2012), we have not detected any trends in patient
selection for ASCT (data in Clark et al.) [21] or any
changes in stem cell mobilisation/harvesting techniques
other than those compared in this report. Nevertheless,
we acknowledge that it would be preferable to have
data from a prospective randomised trial. However, it
is unlikely that such a trial would recruit well, given
the compelling clinical data on plerixafor efficacy and
excellent side effect profile, and there has been little
enthusiasm for such a study within the UK. The inclu-
sion of 11 patients who received plerixafor into control
group 2 means that the costs of the control group
increase predominantly due to the cost of plerixafor
itself. This results in a smaller incremental cost between
treatment and control group 2. These 11 patients may be
similar to other patients historically who failed to mobi-
lise but were treated at a time when plerixafor was avail-
able. The change in practice during the period of
retrospective data collection highlights the disadvantages
of such a comparator group.
Some health economic analyses have been conducted
previously to establish the cost effectiveness of plerixafor
[22,24,26]. However, many of these studies have been
based in the US setting and as health care systems vary
between countries, the results cannot be directly general-
ized [34]. This analysis provides additional evidence in
support of the pre-emptive use of plerixafor as a cost-
effective method for successful mobilisation and prevent-
ing the need for remobilisation. Our results show that
plerixafor tends to dominate in terms of cost and efficacy
in lymphoma patients. For myeloma patients, successful
mobilisation is more likely to be achieved at a higher cost.
However the additional spend required is a cost-effective
use of NHS resources is difficult to determine without a
benchmark of value for successful stem-cell mobilisation.
However, although reaffirmed by other studies, due to the
relatively small sample size of HD patients, caution is
required in the interpretation of some results [36].
Almost all (93%) patients mobilised by plerixafor
yielded enough cells to support a subsequent ASCT (Sce-
nario analysis 3, Table II) after a single round, and this
compares well with the 83% achieving this in the historic
control group, some of whom required additional harvest-
ing rounds. However, the present cost-effectiveness evalu-
ation is confined to the period from initiation of stem cell
mobilisation until its completion. It cannot therefore com-
ment on whether the higher “success rate” of stem cell
mobilisation with plerixafor translates into superior long
term relapse free and overall survival and improved qual-
ity of life, nor whether plerixafor is cost effective in all
patients. For example it is plausible that with first line
plerixafor, additional patients may reach ASCT and more
quickly, resulting in improved outcome, but that this is
offset by the substantial cost of the additional ASCT pro-
cedures. Conversely, a useful by-product of conventional
chemotherapy mobilisation is an anti-tumour effect,
which is absent with plerixafor mobilisation. Moreover,
further studies are required to determine the long term
outcome and additional resource use of patients beyond
completion of stem cell harvest.
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